Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01718743 · OUTCOME

Overall Survival

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2025-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
through out study treatment and up to 30 days after completion of study treatment, up to 119 months

What was measured

Estimated using the Kaplan-Meier method. Cox proportional hazards model will be used to include multiple covariates. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.

Groups in this outcome

Treatment (Ixazomib Citrate, Lenalidomide)

Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Ixazomib Citrate, Lenalidomide)64

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Lenalidomide)NANot reportedNANAThe median OS time is the time point (from transplant) at which the probability of survival is 50%. If you look at the KM curve below for OS, the curve is going down overtime but has not reached the horizontal line for probability=0.5. The median OS time has not been reached. The 95% CI is not estimable.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The median OS time is the time point (from transplant) at which the probability of survival is 50%. If you look at the KM curve below for OS, the curve is going down overtime but has not reached the horizontal line for probability=0.5. The median OS time has not been reached. The 95% CI is not estimable.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      64
    units
    Participants
description
Estimated using the Kaplan-Meier method. Cox proportional hazards model will be used to include multiple covariates. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.
dispersion Type
95% Confidence Interval
groups
  1. description
    Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies
    id
    OG000
    title
    Treatment (Ixazomib Citrate, Lenalidomide)
param Type
MEDIAN
reporting Status
POSTED
time Frame
through out study treatment and up to 30 days after completion of study treatment, up to 119 months
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice